These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15481851)

  • 21. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.
    Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J
    Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanthanum carbonate.
    Swainston Harrison T; Scott LJ
    Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
    Komaba H; Kakuta T; Suzuki H; Hida M; Suga T; Fukagawa M
    Nephrol Dial Transplant; 2015 Jan; 30(1):107-14. PubMed ID: 25422311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial.
    Kurihara S; Tsuruta Y; Akizawa T
    Nephrol Dial Transplant; 2005 Feb; 20(2):424-30. PubMed ID: 15673691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T; Negi S;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
    Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
    Huang W; Liu J; Tang Y; Gao X; Di B; Zhang F
    Curr Med Res Opin; 2014 Jan; 30(1):99-108. PubMed ID: 24063635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
    Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
    Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
    Ando R; Kimura H; Sato H; Iwamoto S; Yoshizaki Y; Chida Y; Ishida Y; Takayama M; Yamada K; Tachibana K; Ohtsuka M; Kikuchi K; Inoue A
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():2-8. PubMed ID: 23586506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.